Stryker Corporation (NYSE:SYK) Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 453,214 shares of the medical technology company's stock after purchasing an additional 25,107 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Stryker worth $168,709,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Capital A Wealth Management LLC purchased a new stake in shares of Stryker during the 4th quarter valued at $26,000. Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the 1st quarter valued at $32,000. City Holding Co. lifted its holdings in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Stryker during the 1st quarter valued at $40,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Stryker during the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded down $4.08 on Thursday, hitting $396.85. The company's stock had a trading volume of 1,036,626 shares, compared to its average volume of 1,443,964. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a fifty day moving average price of $386.10 and a 200-day moving average price of $378.65. The company has a market capitalization of $151.47 billion, a price-to-earnings ratio of 53.63, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the previous year, the firm posted $2.50 EPS. Stryker's revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is 45.41%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on SYK. BTIG Research reiterated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Evercore ISI raised their target price on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Citigroup restated a "buy" rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Sanford C. Bernstein set a $450.00 target price on Stryker in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and a consensus price target of $428.55.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.